US EditionResistance mechanism in chronic lymphocytic leukemia identified - German Cancer Research CenterLogo des Deutschen KrebsforschungszentrumsLogo des Deutschen KrebsforschungszentrumLogo der Deutschen Zentren der GesundheitsforschungLogo des Helmholtzinstitut
Summary by dkfz.de
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Resistance mechanism in chronic lymphocytic leukemia identified - German Cancer Research CenterLogo des Deutschen KrebsforschungszentrumsLogo des Deutschen KrebsforschungszentrumLogo der Deutschen Zentren der GesundheitsforschungLogo des Helmholtzinstitut
The drug ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. These agents, which have only been available for about ten years, have significantly improved the treatment options for chronic lymphocytic leukemia: BTK inhibitors have a targeted effect on the malignant B cells in CLL. They slow down their uncontrolled proliferation by blocking the Bruton's tyrosine kinase. This enzyme plays an important role in the maturation and proliferation o
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
